Tradestie Institutional Equity Comparison Engine

SYRE vs MDGL โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SYRE Overall Edge

SYRE Captures Institutional Edge (3โ€“1 Pillars ยท 3โ€“7 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Spyre Therapeutics, Inc. Common Stock (SYRE) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while MDGL counters with relative strength in Valuation. Fundamentally, SYRE trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MDGL at 38.1x Forward P/E and -10.7% operating margin (+50.1% YoY). In options structure, SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro) against MDGL sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MDGL
SYRE N/M vs MDGL 38.1x Fwd P/E
Growth & Margin Winner SYRE
Op Margin 0.0% vs -10.7% ยท YoY +0.0% vs +50.1%
Momentum & Technical Winner SYRE
1Y +341.7% vs -17.8% ยท 52W Pos 88% vs 27%
Options & Structure Winner SYRE
UNCLASSIFIED (10th %ile IV) vs CONSOLIDATION (13th %ile IV)
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
36.1 / 100 SELL
Tech 8.0 Fund 33.0 Flow 50.0 Mom 50.0
MDGL NASDAQ
Madrigal Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$423.54
-0.9% 1D
Market Cap $9.8B
1M Return -5.83%
1Y Return -17.75%
Forward P/E 38.1x
Unified AI Score
54.0 / 100 HOLD
Tech 73.0 Fund 56.0 Flow 63.0 Mom 58.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: SYRE +341.74% MDGL -17.75% Spread: +359.49 pp (SYRE Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
SYRE TTM Op. Margin: 0.0% MDGL TTM Op. Margin: -10.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs MDGL. Trailing 12-month operating profitability (SYRE 0.0% vs MDGL -10.7%) and valuation multiples (SYRE N/M vs MDGL 38.1x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: SYRE (3) vs MDGL (7)
Institutional Metric SYRE MDGL Criterion Row Winner
Market Capitalization Scale $9.8B $9.8B Larger Scale MDGL
Trailing P/E Ratio Valuation N/M 61.4x Lower Multiple MDGL
Forward P/E Ratio Valuation N/M 38.1x Lower Multiple MDGL
Revenue Growth (YoY) Growth +0.0% +50.1% Higher Growth MDGL
Operating Margin (TTM) Profitability 0.0% -10.7% Higher Margin SYRE
Net Profit Margin Profitability 0.0% -10.9% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -35.0% -24.8% Higher ROE MDGL
52-Week Range Position Momentum 88% ($22โ€“$111) 27% ($354โ€“$615) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 1.75ฮฒ ยท 59% Vol 0.28ฮฒ ยท 49% Vol Lower Realized Risk MDGL
Unified Institutional Score Composite Signal 36.1 / 100 (SELL) 54.0 / 100 (HOLD) Higher Composite MDGL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full SYRE vs MDGL Buy Guide
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MDGL CONSOLIDATION
157d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live MDGL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither SYRE nor MDGL registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.